

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10713808
Filing Date		2003-11-14
First Named Inventor	Dave S.B. Hoon	
Art Unit	1642	
Examiner Name	Sean E. Aeder	
Attorney Docket Number	JWCI 0035 PUSP	

U.S. PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1						

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1	2004/045521	WO	A	2004-06-03	John Wayne Cancer Institute		<input type="checkbox"/>
	2	96/29430	WO	A	1996-09-26	John Wayne Cancer Institute		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS		Remove

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10713808
Filing Date	2003-11-14
First Named Inventor	Dave S.B. Hoon
Art Unit	1642
Examiner Name	Sean E. Aeder
Attorney Docket Number	JWCI 0035 PUSP

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	BALCH ET AL., "Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma," J. Clin. Oncol., 19: 3635-48, 2001	<input type="checkbox"/>
	2	BALCH ET AL., "New TNM Melanoma Staging System: Linking Biology and Natural History to Clinical Outcomes," Semin. Surgical Oncology, 21: 43-52, 2003	<input type="checkbox"/>
	3	BOSTICK ET AL., "Limitations of Specific Reverse-Transcriptase Polymerase Chain Reaction Markers in the Detection of Metastases in the Lymph Nodes and Blood of Breast Cancer Patients," J. Clinical Oncol., 16: 2632-40, 1998	<input type="checkbox"/>
	4	BOURAS ET AL., "Stanniocalcin 2 is an Estrogen-Responsive Gene Coexpressed with the Estrogen Receptor in Human Breast Cancer," Cancer Res., 62: 1289-95, 2002	<input type="checkbox"/>
	5	BUSTIN, "Absolute Quantification of mRNA Using Real-Time Reverse Transcription Polymerase Chain Reaction Assay," J. of Molecular Endocrinology, 25: 169-93, 2000	<input type="checkbox"/>
	6	CHANG ET AL., "Mammalian Stanniocalcins and Cancer," Endocrine-Related Cancer, v. 10: 359-373, 2003	<input type="checkbox"/>
	7	CHOI ET AL., "Comparison of Tyrosinase-Related Protein-2, S-100, and Melan A Immunoreactivity in Canine Amelanotic Melanomas," Vet. Pathology, 40: 713-718, 2003	<input type="checkbox"/>
	8	COULIE ET AL., "A Monoclonal Cytolytic T-Lymphocyte Response Observed in a Melanoma Patient Vaccinated with a Tumor-Specific Antigen Peptide Encoded by Gene MAGE-3," PNAS, v. 98, pp. 10290-10295, 2001	<input type="checkbox"/>
	9	CRISTOFANILLI ET AL., "Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer," N. England J. Med., 351: 781-91, 2004	<input type="checkbox"/>
	10	GAUGLER ET AL., "Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes," J. Exp. Med., 179: 921-30, 1994	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10713808
Filing Date	2003-11-14
First Named Inventor	Dave S.B. Hoon
Art Unit	1642
Examiner Name	Sean E. Aeder
Attorney Docket Number	JWCI 0035 PUSP

11	GLASER ET AL., "Detection of Circulating Melanoma Cells by Specific Amplification of Tyrosinase Complementary DNA is not a Reliable Tumor Marker in Melanoma Patients: A Clinical Two-Center Study," <i>J. Clinical Oncol.</i> , 15: 2818-25, 1997	<input type="checkbox"/>
12	GODING, "Mitf from Neural Crest to Melanoma: Signal Transduction and Transcription in the Melanocyte Lineage," <i>Genes Dev.</i> 14: 1712-28, 2000	<input type="checkbox"/>
13	GRADILONE ET AL., "Detection of CK18, CK20 and EGFR mRNAs in Peripheral Blood of Carcinoma Patients: Correlation with Clinical Stage of Disease," <i>Oncology Reports</i> , v. 10: 217-222, 2003	<input type="checkbox"/>
14	IRIE ET AL., "Human Monoclonal Antibody to Ganglioside GM2 for Melanoma Treatment," <i>Lancet</i> 1: 786-7, 1989	<input type="checkbox"/>
15	JUNG ET AL., "Evaluation of Tyrosinase mRNA as a Tumor Marker in the Blood of Melanoma Patients," <i>J. Clinical Oncol.</i> , 15: 2826-31, 1997	<input type="checkbox"/>
16	KAWAKAMI ET AL., "Cloning of the Gene Coding for a Shared Human Melanoma Antigen Recognized by Autologous T Cells Infiltrating into Tumor," <i>Proc. Natl. Acad. Sci. USA</i> , 91: 3515-9, 1994	<input type="checkbox"/>
17	KAWAKAMI ET AL., "Identification of the Immunodominant Peptides of the MART-1 Human Melanoma Antigen Recognized by the Majority of HLA-A2-Restriction Tumor Infiltrating Lymphocytes," <i>J. Exp. Med.</i> , 180: 347-52, 1994	<input type="checkbox"/>
18	KEILHOLZ, ULRICH ET AL., "Quantitative Detection of Circulating Tumor Cells in Cutaneous and Ocular Melanoma and Quality Assessment by Real-time Reverse Transcriptase-Polymerase Chain Reaction," <i>Clinical Cancer Research</i> , v. 10, March 1, 2004, pp. 1605-1612	<input type="checkbox"/>
19	KOYANAGI ET AL., "Multimarker Quantitative Real-Time PCR Detection of Circulating Melanoma Cells in Peripheral Blood: Relation to Disease Stage in Melanoma Patients," <i>Clinical Chem.</i> , 51: 981-8, 2005	<input type="checkbox"/>
20	MARCHETTI ET AL., "mRNA Markers of Breast Cancer Nodal Metastases: Comparison Between Mammaglobin and Carcinoembryonic Antigen in 248 Patients," <i>J. Pathology</i> , v. 195, 186-190, 2001	<input type="checkbox"/>
21	MARINCOLA ET AL., "Escape of Human Solid Tumors from T-Cell Recognition: Molecular Mechanisms and Functional Significance," <i>Adv. Immunol.</i> 74: 181-373, 2000 should this be 181-273	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10713808
Filing Date	2003-11-14
First Named Inventor	Dave S.B. Hoon
Art Unit	1642
Examiner Name	Sean E. Aeder
Attorney Docket Number	JWCI 0035 PUSP

22	PANTEL ET AL., "Detection and Clinical Importance of Micrometastatic Disease," J. Natl. Cancer Inst., 91, 1113-24, 1999	<input type="checkbox"/>
23	PENG ET AL., "Multiple PCR Analyses on Trace Amounts of DNA Extracted from Fresh and Paraffin Wax Embedded Tissues After Random Hexamer Primer PCR Amplification," J. Clinical Pathology, v. 47, pp. 605-608, 1994	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button [Add](#)

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.